ATE393629T1 - Verwendung von cci-779 als antineoplastisches mittel - Google Patents

Verwendung von cci-779 als antineoplastisches mittel

Info

Publication number
ATE393629T1
ATE393629T1 AT01996175T AT01996175T ATE393629T1 AT E393629 T1 ATE393629 T1 AT E393629T1 AT 01996175 T AT01996175 T AT 01996175T AT 01996175 T AT01996175 T AT 01996175T AT E393629 T1 ATE393629 T1 AT E393629T1
Authority
AT
Austria
Prior art keywords
cci
antineoplastic agent
antineoplastic
agent
Prior art date
Application number
AT01996175T
Other languages
English (en)
Inventor
Gary Dukart
James Gibbons
Lisa Speicher
Philip Frost
Carolyn Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE393629T1 publication Critical patent/ATE393629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01996175T 2000-11-15 2001-11-13 Verwendung von cci-779 als antineoplastisches mittel ATE393629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24907700P 2000-11-15 2000-11-15

Publications (1)

Publication Number Publication Date
ATE393629T1 true ATE393629T1 (de) 2008-05-15

Family

ID=22941961

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996175T ATE393629T1 (de) 2000-11-15 2001-11-13 Verwendung von cci-779 als antineoplastisches mittel

Country Status (27)

Country Link
US (3) US20020091137A1 (de)
EP (1) EP1335725B1 (de)
JP (4) JP4472251B2 (de)
KR (1) KR100827942B1 (de)
CN (2) CN1678312A (de)
AR (1) AR031341A1 (de)
AT (1) ATE393629T1 (de)
AU (2) AU2731302A (de)
BR (1) BR0115323A (de)
CA (1) CA2429020C (de)
CY (1) CY1108109T1 (de)
DE (1) DE60133831T2 (de)
DK (1) DK1335725T3 (de)
EA (1) EA007096B1 (de)
ES (1) ES2305134T3 (de)
HU (1) HUP0400521A3 (de)
IL (2) IL155871A0 (de)
MX (1) MXPA03004192A (de)
NO (1) NO20032181L (de)
NZ (1) NZ539668A (de)
PL (1) PL207061B1 (de)
PT (1) PT1335725E (de)
SG (1) SG148031A1 (de)
SI (1) SI1335725T1 (de)
TW (1) TWI286074B (de)
WO (1) WO2002040000A2 (de)
ZA (1) ZA200304603B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP3342411B1 (de) 2001-02-19 2019-08-21 Novartis Pharma AG Rapamycin-derivat zur behandlung von bauchspeicheldrüsenkrebs
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
IL158800A0 (en) * 2001-06-01 2004-05-12 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
JP4547911B2 (ja) * 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
WO2004002367A1 (en) * 2002-06-27 2004-01-08 Microport Medical (Shanghai) Co., Ltd. Drug eluting stent
PT1553940E (pt) * 2002-07-30 2008-05-09 Wyeth Corp Formulações parentéricas contendo um hidroxi-éster de rapamicina
BR0314397A (pt) * 2002-09-17 2005-08-09 Wyeth Corp Formulações orais
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
WO2004072265A2 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (de) * 2003-04-22 2007-01-24 Wyeth Antineoplastische zusammensetzungen
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
JP2007500191A (ja) * 2003-07-25 2007-01-11 ワイス Ｃｃｉ−７７９の凍結乾燥処方
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
PL1701698T3 (pl) * 2004-01-08 2008-03-31 Wyeth Corp Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
KR20070104908A (ko) * 2005-02-15 2007-10-29 와이어쓰 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물
KR101354828B1 (ko) * 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
NO20220050A1 (no) * 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
AU2006331874A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
EP2198554B1 (de) * 2007-10-03 2016-03-23 Genesis Technical Systems, Corp. Dynamische asymmetrische ringe
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es) 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
EP2416774B1 (de) 2009-04-06 2015-11-04 Wyeth LLC Behandlungsschema mit neratinib gegen brustkrebs
US8716307B2 (en) * 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
JP2013527223A (ja) * 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
US9745941B2 (en) * 2014-04-29 2017-08-29 Ford Global Technologies, Llc Tunable starter resistor
KR101965319B1 (ko) * 2015-08-24 2019-04-04 샨시 야바오 헬스 프로덕츠 컴퍼니 리미티드 항종양 약물 제조에서의 다이하이드록시아세톤의 용도
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
DK1318837T3 (da) 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
US20070142425A1 (en) 2007-06-21
TWI286074B (en) 2007-09-01
SI1335725T1 (sl) 2008-08-31
MXPA03004192A (es) 2003-09-22
CA2429020A1 (en) 2002-05-23
JP2016094444A (ja) 2016-05-26
JP4472251B2 (ja) 2010-06-02
AU2731302A (en) 2002-05-27
CN102058588A (zh) 2011-05-18
KR20040029309A (ko) 2004-04-06
CN1678312A (zh) 2005-10-05
EP1335725B1 (de) 2008-04-30
ES2305134T3 (es) 2008-11-01
EP1335725A2 (de) 2003-08-20
AR031341A1 (es) 2003-09-17
CA2429020C (en) 2009-05-26
NO20032181D0 (no) 2003-05-14
HUP0400521A2 (hu) 2004-06-28
NO20032181L (no) 2003-05-14
JP2014088430A (ja) 2014-05-15
EA007096B1 (ru) 2006-06-30
AU2007201324B2 (en) 2010-11-18
KR100827942B1 (ko) 2008-05-13
US20020091137A1 (en) 2002-07-11
AU2007201324A1 (en) 2007-04-19
DK1335725T3 (da) 2008-06-30
SG148031A1 (en) 2008-12-31
JP2010018620A (ja) 2010-01-28
US7189735B2 (en) 2007-03-13
DE60133831D1 (de) 2008-06-12
PL207061B1 (pl) 2010-10-29
EA200300566A1 (ru) 2003-10-30
IL155871A (en) 2012-03-29
ZA200304603B (en) 2004-09-13
NZ539668A (en) 2007-06-29
WO2002040000A2 (en) 2002-05-23
PL362740A1 (en) 2004-11-02
HK1058008A1 (en) 2004-04-30
US20030153593A1 (en) 2003-08-14
IL155871A0 (en) 2003-12-23
PT1335725E (pt) 2008-06-19
BR0115323A (pt) 2004-02-17
DE60133831T2 (de) 2009-05-20
CY1108109T1 (el) 2014-02-12
JP2004517065A (ja) 2004-06-10
HUP0400521A3 (en) 2007-05-29
WO2002040000A3 (en) 2002-09-06
US7781446B2 (en) 2010-08-24

Similar Documents

Publication Publication Date Title
ATE393629T1 (de) Verwendung von cci-779 als antineoplastisches mittel
DE60026540D1 (de) Mutilin-derivate und ihre anwendung als antibakterielle mittel
ATE391531T1 (de) Schweisshemmende mittel
DE60031513D1 (de) Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten
DE60214413D1 (de) Thiophen- und thiazolsulfonamide als antineoplastische mittel
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE359275T1 (de) Substituierte bizyclische derivate verwendbar als antitumor mittel
DE60134094D1 (de) C7-taxanester als antitumormittel
DE60127997D1 (de) 1,5-benzothiazepine und ihre verwendung als antihyperlipidämika
DE60132618D1 (de) 4,6-diphenylpyridinderivate als entzündungshemmende mittel
NO20021116D0 (no) Ny sammensetning
DE50110553D1 (de) Verwendung herbizider Mittel
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
NO20021115D0 (no) Ny sammensetning
DE69806141D1 (de) Indazoleamid-verbindungen als serotoninergene mittel
ATE437860T1 (de) 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
DE69917451D1 (de) Sulfonylbenzolverbindungen als analgetische und entzündungshemmende mittel
DE60114850D1 (de) 10-aryl-11h-benzo[b]fluoren-derivate und analoga als östrogene mittel
DE60230470D1 (de) Festes kosmetisches Mittel
NO20013337L (no) Ny behandling
DE69921983D1 (de) Indolderivate als serotonergische mittel
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
DE60120711D1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
DE60201463D1 (de) Indanon-Derivate als Duftstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1335725

Country of ref document: EP

REN Ceased due to non-payment of the annual fee